抗聚乙二醇抗体抑制治疗性聚乙二醇化凝血因子VIII的促凝血活性
该研究在2例轻型血友病A患者中描述了针对40 kDa聚乙二醇化凝血因子VIII(40PEG-BDDFVIII)产生的抗体。46例接受治疗患者中2例出现抑制性抗体,抗PEG抗体可抑制所有现有聚乙二醇化治疗药物但程度不同,换用非聚乙二醇化凝血因子VIII后两例患者凝血因子VIII活性均成功升高。
要点
- 46例接受40PEG-BDDFVIII治疗患者中2例产生针对该药的抑制性抗体。
- 两例患者换用非聚乙二醇化凝血因子VIII后凝血因子VIII活性均成功升高。
- 患者抗PEG抗体及AGP3可抑制所有现有聚乙二醇化治疗药物但程度不同。
核心结论
- 针对40PEG-BDDFVIII聚乙二醇部分的抗体消除了该药疗效。
- 这是首例轻型血友病A患者接受聚乙二醇化凝血因子VIII治疗后产生中和性抗PEG抗体的真实世界报告。
研究设计与样本
- 研究纳入2例接受40PEG-BDDFVIII治疗的轻型血友病A患者,并开发了基于微珠的免疫分析法来表征和确认检测到的抗体特异性。
- 通过改良Nijmegen-Bethesda法测定抗体对聚乙二醇化治疗药物的中和性质。
主要发现
- 46例接受40PEG-BDDFVIII治疗的患者中2例产生了针对该药的抑制性抗体。
- 换用非聚乙二醇化凝血因子VIII后,两例患者的凝血因子VIII活性均成功升高。
- 患者1产生了针对凝血因子VIII和PEG的抗体,抗凝血因子VIII抗体为免疫球蛋白(Ig)G同种型,抗PEG抗体为IgG、IgM和IgA同种型。
- 患者2的IgG和IgA同种型抗体仅针对PEG部分,竞争性试验确认了抗体对PEG的特异性。
- Nijmegen-Bethesda法显示,患者抗PEG抗体和AGP3(针对PEG骨架的抗体)可抑制所有现有聚乙二醇化治疗药物但程度不同,未检测到抑制性凝血因子VIII抗体。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The standard therapy for patients with hemophilia A (HA) is the replacement with factor VIII (FVIII) therapeutics. To overcome the limitation of short half-life of wild-type FVIII protein, polyethylene glycol (PEG) can be coupled to therapeutic FVIII to improve pharmacokinetics. OBJECTIVES: We aimed to characterize antibodies developed against a FVIII therapeutic PEGylated with a 40-kDa PEG (40PEG-BDDFVIII) in 2 patients with mild HA. METHODS: An inhouse bead-based immunoassay was developed to characterize and confirm the specificity of the detected antibodies. The neutralizing nature of the antibodies toward PEGylated therapeutics was determined by a modified Nijmegen-Bethesda assay. RESULTS: Two out of 46 patients treated with 40PEG-BDDFVIII developed inhibitory antibodies toward the drug. Switching to a non-PEGylated FVIII successfully increased the FVIII activity in both patients. In patient 1, antibodies were raised against FVIII and PEG. Anti-FVIII antibodies were of the immunoglobulin (Ig)G isotype, whereas anti-PEG antibodies were of IgG, IgM, and IgA isotypes. In patient 2, antibodies of IgG and IgA isotypes were directed only against the PEG moiety. Competitive assays confirmed the specificity of the antibodies against PEG. The applied Nijmegen-Bethesda assay revealed that patients' anti-PEG antibodies and AGP3, an antibody against the backbone of PEG, can inhibit all currently available PEGylated therapeutics but to different degrees. No inhibitory FVIII antibodies were detected. CONCLUSION: Antibodies against the PEG moiety of 40PEG-BDDFVIII abolished the efficacy of the drug. This is the first report on real-world experiences with the development of neutralizing anti-PEG antibodies after treatment with PEGylated FVIII therapeutics in mild HA.
引用
- Pezeshkpoor B, Sereda N, Berkemeier AC, et al. Antidrug antibodies against the polyethylene glycol moiety inhibit the procoagulant activity of therapeutic polyethylene glycolated factor VIII. J Thromb Haemost. 2023. PMID: 36934798. doi:10.1016/j.jtha.2023.03.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。